ΒΆ gastric ulcers
ΒΆ Definition
Erosions extending through the gastric mucosa into the submucosa, resulting from loss of epithelial integrity when aggressive factors (acid, pepsin, H. pylori, NSAIDs) overwhelm protective mechanisms (mucus bicarbonate layer, prostaglandin-mediated mucosal blood flow, epithelial renewal). Ulceration represents failure of the mucosal barrier to withstand pH 1.5 luminal acid β a deficit in the evolutionary trade-off between pathogen defense (strong acid) and tissue self-protection.
ΒΆ Picture It
Imagine a fortress wall (gastric mucosa) defending a city from a constantly bubbling acid moat outside. The wall has three layers of protection: (1) a thick slime coating (mucus-bicarbonate layer) that neutralizes acid before it reaches the stone; (2) repair crews (prostaglandins) that continuously patrol, fixing cracks and ensuring blood flow brings fresh materials; (3) sentries (epithelial cells) that regenerate every 3-5 days to replace damaged stones.
Now introduce saboteurs: NSAIDs fire the repair crews (block COX-1 β no PGE2), so cracks don't get fixed and blood flow drops. H. pylori bacteria drill through the slime layer and trigger chronic fire alarms (inflammation), exhausting the garrison. Chronic stress diverts the city's budget away from wall maintenance (cortisol suppresses prostaglandin synthesis). Eventually, the acid moat breaks through a weak spot β that's your ulcer.
The conventional medical response? Install massive pumps to drain the acid moat entirely (PPIs). Problem: without the moat's pathogen-killing power, enemy bacteria colonize the city (SIBO), the city becomes dependent on the pumps (rebound hyperacidity), and nutrient supply lines break down (malabsorption). The real solution requires restoring the repair crews, rebuilding the slime layer, and removing the saboteurs β not just draining the moat.
ΒΆ Mechanism
Ulcer formation occurs through multiple converging pathways:
ΒΆ Protective Mechanisms (Normally Active)
-
Prostaglandin defense: Gastric epithelial cells constitutively express COX-1 β PGE2 synthesis β EP2/EP4 receptor activation β cAMP β PKA β multiple protective effects:
- Increased mucus secretion from surface mucus cells
- Bicarbonate secretion (neutralizes H+ at epithelial surface)
- Mucosal blood flow maintenance (delivers oxygen, nutrients, bicarbonate)
- Inhibition of parietal cell HβΊ/KβΊ-ATPase (negative feedback on acid secretion)
-
Mucus-bicarbonate barrier: Surface mucus cells secrete MUC5AC gel (200-400 ΞΌm thick) + HCOββ» β pH gradient from 1.5 (lumen) to 6.5 (epithelial surface)
-
Epithelial renewal: Pit cells divide every 24-48h, complete surface replacement every 3-5 days
ΒΆ Pathway to Ulceration
NSAID-induced pathway:
H. pylori pathway:
- Bacteria colonize gastric antrum β urease enzyme β NHβ production β local pH neutralization β survival in acidic environment
- Bacterial adhesins bind epithelial cells β CagA pathogenicity island translocation β epithelial cytoskeletal disruption
- Flagellar motility β penetration through mucus layer
- VacA toxin β epithelial cell vacuolation and apoptosis
- LPS activation of TLR4 β NF-ΞΊB β IL-1Ξ², IL-6, IL-8, TNF-Ξ± production
- Chronic inflammation β Th17 polarization β IL-17 β neutrophil recruitment β tissue damage
- Somatostatin-secreting D cells destroyed β loss of acid inhibition β gastrin elevation β parietal cell hyperplasia β increased acid output
- Decades of inflammation β gastric atrophy β intestinal metaplasia β dysplasia β gastric adenocarcinoma (1-3% of infected individuals)
Stress pathway:
- Chronic stress β sustained cortisol elevation β GR activation β transcriptional suppression of COX-2 (inducible form) and COX-1
- Cortisol β β VEGF β reduced angiogenesis β impaired mucosal healing
- Sympathetic activation β splanchnic vasoconstriction β mucosal ischemia
- CRH β mast cell degranulation β histamine release β parietal cell activation
Hypochlorhydria paradox:
- PPI overuse β achlorhydria β bacterial overgrowth (normal stomach <10Β³ CFU/mL, PPI use >10βΆ CFU/mL)
- Bacterial translocation β mucosal immune activation β compensatory inflammation
- G-cell hyperplasia (feedback response to low acid) β hypergastrinemia β ECL cell proliferation β potential gastric neuroendocrine tumors
- Loss of acid barrier β increased antigen exposure β food sensitivities
ΒΆ Inflammatory Perpetuation
Once initiated, ulcers self-perpetuate:
- Tissue damage β DAMPs release (HMGB1, S100 proteins) β TLR4/RAGE activation
- Neutrophils β myeloperoxidase β HOCl β further epithelial damage
- Macrophages β TNF-Ξ±, IL-1Ξ² β COX-2 induction β PGE2 (pro-inflammatory isoform) β edema, pain
- Fibrin deposition β impaired oxygen diffusion
- Pepsin (optimally active pH 1.5-3.5) β protein degradation of exposed submucosa
ΒΆ Clinical Significance
ΒΆ Evolutionary Context
Gastric acid at pH 1.5 is among the strongest in the animal kingdom β a conserved trait across 400 million years of vertebrate evolution. This represents massive energy investment (HβΊ/KβΊ-ATPase consumes 30-40% of gastric mucosal ATP) for a critical function: pathogen sterilization. Humans evolved as scavengers consuming partially decayed carcasses; strong acid was survival insurance against food-borne pathogens.
The evolutionary mismatch: modern triggers (NSAIDs, chronic psychological stress, processed foods lacking protective factors) were not present during our evolutionary history. We're experiencing gastric ulcers because our Stone Age stomach meets Space Age stressors.
ΒΆ Clinical Thresholds and Diagnostics
- H. pylori prevalence: 50-90% in gastric ulcers (varies by population, decreasing in developed nations)
- NSAID use: 15-30% of chronic NSAID users develop ulcers; risk increases with age >65, concurrent corticosteroids, anticoagulants
- Gastric pH: Normal 1.5-3.5; PPI therapy elevates to 4-6; pH >4 allows bacterial overgrowth
- Gastrin levels: Normal <100 pg/mL; PPI therapy β 200-500 pg/mL (rebound hypergastrinemia)
- Pepsinogen I/II ratio:
.0 indicates atrophic gastritis (ulcer sequelae)
ΒΆ cPNI Intervention Framework
Metamodel 5 application (addressing root causes, not symptoms):
- Remove saboteurs: Discontinue NSAIDs where possible; eradicate H. pylori using triple therapy (PPI + amoxicillin + clarithromycin) but only as bridge, not long-term solution
- Restore protective mechanisms:
- Zinc carnosine (75-150 mg BID): Binds to ulcer site, stimulates mucus production, inhibits H. pylori adhesion
- DGL (deglycyrrhizinated licorice): Increases mucus quality and quantity, prostaglandin synthesis
- Vitamin C (1000 mg/day): Required for collagen synthesis in healing; also inhibits H. pylori growth
- Glutamine (5-10g/day): Primary fuel for enterocytes, enhances tight junction proteins
- Address stress axis: HPA axis modulation through breathwork, vagal tone enhancement, adaptogenic herbs (Rhodiola rosea 400-600mg, Ashwagandha 300-600mg) β reduces cortisol-mediated prostaglandin suppression
- Nutritional support:
- Cabbage juice: Traditional remedy, contains S-methylmethionine (vitamin U) which stimulates prostaglandin synthesis β 1 liter/day shows ulcer healing in 7-10 days (historical studies)
- Omega-3 fatty acids (EPA/DHA 2-3g/day): Substrate for resolvins and protectins, reduces inflammatory cascade
- Manuka honey (medical grade, MGO >400): Bactericidal against H. pylori, stimulates tissue repair
- Restore acid function gradually: After healing, wean off PPIs using betaine HCl protocol to prevent SIBO and restore digestive capacity
ΒΆ Long-term Complications of Conventional Treatment
- Nutrient malabsorption: Achlorhydria β impaired B12, iron, calcium, magnesium absorption β anemia, osteoporosis
- SIBO prevalence: 50-70% in long-term PPI users vs. 6-15% in general population
- Clostridium difficile risk: 1.4-2.7Γ increased risk (loss of acid barrier)
- Pneumonia risk: 1.3-1.9Γ increased (bacterial overgrowth β aspiration)
- Rebound hyperacidity: Discontinuation β gastrin-mediated acid surge β dependency cycle
- Gastric polyps: Fundic gland polyps in 10-40% of long-term users (>1 year)
ΒΆ Integration with Selfish Systems
The selfish immune system prioritizes acute threat response over long-term tissue integrity. Chronic inflammation from H. pylori triggers decades of collateral damage to host tissue because the immune system cannot fully clear the infection (H. pylori evades immunity through phase variation, mimicry of host antigens). The resulting atrophy and cancer risk represents antagonistic pleiotropy β early-life immune activation benefits survival, but creates late-life pathology.
ΒΆ Key Facts
- Normal gastric pH is 1.5 β capable of dissolving metal and killing 99.9% of ingested bacteria within 15 minutes
- Parietal cells secrete 2-3 liters of HCl daily, requiring HβΊ/KβΊ-ATPase to pump against 3 million-fold concentration gradient
- PGE2 from COX-1 is the primary mucosal protectant; NSAIDs remove this brake while leaving acid secretion intact
- H. pylori infects 50% of global population but only 10-15% develop ulcers β host genetics (IL-1Ξ² polymorphisms) determine risk
- Gastric epithelial turnover is 3-5 days β among the fastest in the body, reflecting constant acid exposure stress
- Hypochlorhydria (pH >3.5) paradoxically increases ulcer risk through bacterial overgrowth and compensatory inflammation
- Gastrin levels >500 pg/mL on PPI therapy indicate severe acid suppression and rebound risk
- Phylogenetic conservation of gastric acid: pH 1.5-2.5 across fish, amphibians, reptiles, birds, and mammals (scavengers)
- Ulcer healing requires 6-8 weeks even with optimal therapy; epithelial migration rate is 50-100 ΞΌm/day
- Vitamin C concentrations in gastric juice are 10-fold higher than plasma (active secretion) β role in collagen synthesis for healing
- Stress ulcers (Cushing's ulcers, Curling's ulcers) can develop within hours in ICU patients due to splanchnic hypoperfusion
- Capsaicin (chili peppers) stimulates TRPV1 β calcitonin gene-related peptide (CGRP) release β mucosal blood flow increase β protective effect
ΒΆ Connections
- gastric acid β the primary aggressive factor that ulcerates mucosa when protective mechanisms fail; evolutionary adaptation for pathogen defense creates vulnerability to modern triggers
- proton pump inhibitor β blocks HβΊ/KβΊ-ATPase to suppress acid but creates dependency, SIBO, and nutrient malabsorption; treats symptom rather than cause
- Helicobacter pylori β Gram-negative bacterium that colonizes 50% of humans; urease production, CagA/VacA virulence factors trigger chronic inflammation leading to ulceration and cancer
- NSAIDs β inhibit COX-1 constitutively expressed in gastric mucosa, eliminating PGE2-mediated protection; responsible for 30% of ulcers in elderly
- PGE2 β critical cytoprotective prostaglandin that maintains mucus secretion, bicarbonate production, mucosal blood flow, and inhibits acid secretion via EP2/EP4 receptors
- COX-1 β constitutive enzyme producing protective PGE2 in stomach; NSAID inhibition removes mucosal defense while leaving acid secretion intact
- COX-2 β inducible enzyme during inflammation producing both pro- and anti-inflammatory prostaglandins; suppressed by chronic cortisol
- hypochlorhydria β low acid state from PPI overuse or atrophic gastritis; allows bacterial overgrowth, nutrient malabsorption, and paradoxically increases ulcer risk through inflammation
- gastritis β superficial inflammation of gastric mucosa that precedes ulceration; chronic H. pylori gastritis progresses through atrophy to metaplasia to dysplasia
- gastric atrophy β end-stage consequence of chronic inflammation; loss of parietal and chief cells, reduced acid and pepsinogen, increased cancer risk
- gastro-oesophageal reflux disease β shares acid-related pathology but involves lower esophageal sphincter dysfunction; often co-exists with gastric ulcers
- Th17 β pro-inflammatory T cell subset producing IL-17 that recruits neutrophils; accumulates in H. pylori-infected gastric mucosa perpetuating tissue damage
- cortisol β chronic elevation from stress suppresses COX-1/COX-2 transcription, reduces VEGF-mediated angiogenesis, impairs ulcer healing
- chronic stress β activates HPA axis and sympathetic nervous system, reducing mucosal blood flow and prostaglandin synthesis; major ulcer risk factor
- parietal cell β gastric cell producing HCl via HβΊ/KβΊ-ATPase and intrinsic factor; hyperplasia from chronic gastrin elevation in H. pylori infection increases acid load
- mucus layer β MUC5AC glycoprotein gel (200-400 ΞΌm thick) creating pH gradient from 1.5 to 6.5; physical and chemical barrier disrupted by NSAIDs and H. pylori
- bicarbonate β secreted by surface mucous cells into mucus layer; neutralizes acid at epithelial surface; production dependent on prostaglandins
- barrier dysfunction β fundamental pathophysiological mechanism allowing luminal acid to damage epithelium; applies across gut, blood-brain barrier, skin
- chronic inflammation β perpetuates tissue damage through neutrophil ROS, macrophage cytokines, and impaired resolution; prevents ulcer healing
- evolutionary mismatch β gastric ulcers exemplify conflict between evolved strong acid (pathogen defense) and modern environmental triggers (NSAIDs, chronic stress, processed foods)
- SIBO β small intestinal bacterial overgrowth consequence of PPI-induced hypochlorhydria; bacteria translocate and trigger mucosal inflammation compounding gastric damage
- nutrient malabsorption β achlorhydria from PPI use impairs ionization and absorption of B12, iron, calcium, magnesium; leads to anemia, osteoporosis, neuropathy
- TNF-Ξ± β pro-inflammatory cytokine produced by macrophages during H. pylori infection; activates NF-ΞΊB, induces COX-2, perpetuates inflammation
- IL-1Ξ² β key pro-inflammatory cytokine in gastric inflammation; genetic polymorphisms increasing IL-1Ξ² production elevate ulcer and gastric cancer risk 2-3 fold
- neutrophils β first responders to mucosal damage; release myeloperoxidase, elastase, and ROS causing collateral epithelial injury and delayed healing
- tight junctions β ZO-1, occludin, claudin proteins maintaining epithelial barrier; disrupted by H. pylori and inflammatory cytokines allowing acid penetration
- reactive oxygen species β generated by neutrophils (via NADPH oxidase) and damaged mitochondria; cause lipid peroxidation and DNA damage perpetuating ulceration
- VEGF β vascular endothelial growth factor essential for mucosal angiogenesis and healing; suppressed by chronic cortisol and NSAIDs
- glutamine β primary fuel for gastric epithelial cells; supplementation (5-10g/day) enhances tight junction proteins and accelerates healing
- vitamin C synthesis β humans lost GULO gene, requiring dietary intake; gastric juice vitamin C 10Γ plasma concentrations for collagen synthesis during healing
- zinc carnosine β chelated complex that adheres to ulcer sites; stimulates mucus production, inhibits H. pylori, and provides zinc for metalloproteases in healing
- resolvin D-series β specialized pro-resolving mediators derived from DHA; RvD1 and RvD2 promote neutrophil apoptosis, macrophage efferocytosis, and resolution of gastric inflammation
ΒΆ Module References
- Module 6